Business Context and Reporting Period
This Form 6-K filing by Evotec SE (Evotec AG) dated May 5, 2008, reports the successful completion of the acquisition of Renovis, Inc. on May 2, 2008. Following the merger, Renovis became a wholly owned subsidiary of Evotec. The combined entity's American Depository Shares (ADSs) began trading on the NASDAQ Global Market under the symbol "EVTCV" on a "when issued" basis, with normal trading under "EVTC" anticipated within two weeks.
Key Financial Metrics
The filing provides limited financial data, focusing primarily on liquidity and capital structure resulting from the merger:
- Liquidity: Pro-forma cash and investments are approximately US$188 million as of March 31, 2008.
- Capital Structure: Evotec issued an aggregate of 34,970,268 new ordinary shares underlying the ADSs. The exchange ratio was 0.5271 ADSs for each outstanding share of Renovis common stock.
- Ownership: Current Evotec stockholders own approximately 68.8% of the combined company, while Renovis stockholders own up to 31.2%.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the reporting period.
- Debt: The filing text does not provide specific debt figures.
Material Changes
The primary material change is the consolidation of Evotec and Renovis. This transaction combines Evotec's drug discovery and development capabilities with Renovis's medicinal chemistry and target validation expertise. The merger expands the company's pipeline to include three clinical candidates and a strong late-stage preclinical pipeline focusing on neurological and inflammatory diseases. Additionally, the Executive Management Team and Supervisory Board have been restructured to include key personnel from Renovis.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Cash Runway: Management expects cash to last through 2010.
- Pipeline Milestones: By the end of 2009, the company expects to have at least six compounds in clinical development, with three expected to have proof-of-concept data to attract partners.
- Clinical Programs:
- EVT 201 (Insomnia): Intends to partner in 2008 following positive Phase II data.
- EVT 101 (Alzheimer's/Pain): Additional Phase Ib data expected in the current quarter.
- EVT 302 (Smoking Cessation): Phase II studies expected to read out in Q3 2008 and H1 2009.
- Preclinical Pipeline: VR1 antagonists (in collaboration with Pfizer) and P2X7 antagonists are expected to enter human clinical trials in 2008. P2X3 antagonists are expected to enter trials in H1 2009.
Risks and Contingencies:
The filing includes a forward-looking statement warning of risks including failure to successfully integrate the businesses, unexpected costs or liabilities, failure to realize synergies, disruption to customer and employee relationships, competition, technological changes, intellectual property issues, and exchange rate fluctuations.
Investor Verification Checklist
- Verify the exact timing of the transition from "EVTCV" to "EVTC" trading symbols on NASDAQ.
- Confirm the pro-forma cash position of US$188 million against the most recent audited financial statements.
- Monitor the progress of the EVT 201 partnership discussions expected in 2008.
- Track the release of additional Phase Ib data for EVT 101 and Phase II results for EVT 302 as scheduled.
- Review the Form F-4 Registration Statement for detailed risk factors regarding the merger integration.